Ekso Bionics Holdings Q4 2023 GAAP EPS $(0.220) Misses $(0.110) Estimate, Sales $4.847M Beat $4.773M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ekso Bionics Holdings reported Q4 2023 GAAP EPS of $(0.220), missing the $(0.110) estimate, but sales of $4.847M exceeded the $4.773M estimate, marking a 36.50% increase from the previous year.
March 04, 2024 | 9:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ekso Bionics Holdings missed EPS estimates by 100% but exceeded sales forecasts by 1.55% in Q4 2023, with a significant year-over-year sales growth of 36.50%.
The missed EPS estimate by a significant margin could concern investors about profitability, while the sales beat and notable year-over-year growth might indicate strong demand and operational success. The mixed results present a neutral short-term outlook as investors weigh the implications of both the earnings miss and the sales beat.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100